Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
21 juin 2024 07h00 HE
|
Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the...
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
17 juin 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
11 juin 2024 16h05 HE
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
AI Brain Health Leader Omniscient Closes Series C Funding Round
11 juin 2024 11h00 HE
|
Omniscient Neurotechnology
Omniscient secures Series C funding to expand Quicktome® platform, advancing connectomics for improved brain health diagnostics and treatments.
Arvinas to Participate in Upcoming Investor Conferences
03 juin 2024 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain
28 mai 2024 09h00 HE
|
Precision Neuroscience
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the...
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
28 mai 2024 08h00 HE
|
Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
Precision Neuroscience Expands Clinical Research In Brain–Computer Interface
22 mars 2024 08h30 HE
|
Precision Neuroscience
NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at...
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
07 mars 2024 07h00 HE
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
27 févr. 2024 08h00 HE
|
Healis Therapeutics
CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.